MCID: SPC010
MIFTS: 47

Speech and Communication Disorders

Categories: Mental diseases

Aliases & Classifications for Speech and Communication Disorders

MalaCards integrated aliases for Speech and Communication Disorders:

Name: Speech and Communication Disorders 40 42
Communication Disorder 40 12 15
Language Disorders 54 43 71
Language Disorder 40 12 15
Communication Disorders 54 43
Speech and Language Disorder 71
Speech Language Disorder 40
Speech-Language Disorder 39
Communication Impairment 71

Classifications:



External Ids:

Disease Ontology 12 DOID:2033 DOID:93
NCIt 49 C2958 C97155
SNOMED-CT 67 62305002 74825008
ICD10 32 F80.9
UMLS 71 C0009460 C0023009 C0023015

Summaries for Speech and Communication Disorders

MedlinePlus : 42 Many disorders can affect our ability to speak and communicate. They range from saying sounds incorrectly to being completely unable to speak or understand speech. Causes include Hearing disorders and deafness Voice problems, such as dysphonia or those caused by cleft lip or palate Speech problems like stuttering Developmental disabilities Learning disabilities Autism spectrum disorder Brain injury Stroke Some speech and communication problems may be genetic. Often, no one knows the causes. By first grade, about 5 percent of children have noticeable speech disorders. Speech and language therapy can help. NIH: National Institute on Deafness and Other Communication Disorders

MalaCards based summary : Speech and Communication Disorders, also known as communication disorder, is related to stuttering and alexia, and has symptoms including lethargy, other symbolic dysfunction and aprosodia. An important gene associated with Speech and Communication Disorders is FOXP2 (Forkhead Box P2), and among its related pathways/superpathways is Neuroscience. The drugs Oxcarbazepine and Methylprednisolone have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and tongue, and related phenotypes are behavior/neurological and growth/size/body region

Disease Ontology : 12 A communication disorder that involves the processing of linguistic information.

Wikipedia : 74 A communication disorder is any disorder that affects an individual's ability to comprehend, detect, or... more...

Related Diseases for Speech and Communication Disorders

Diseases related to Speech and Communication Disorders via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 237)
# Related Disease Score Top Affiliating Genes
1 stuttering 32.9 FOXP2 CNTNAP2 ASPRV1
2 alexia 32.8 MAPT GRN CBSL ASPRV1 APOE
3 speech disorder 32.7 TARDBP MAPT KIAA0319 GRN FOXP2 CNTNAP2
4 dyslexia 32.6 KIAA0319 IQCB1 FOXP2 DNAAF4 CNTNAP2 CMIP
5 expressive language disorder 32.4 FOXP2 CMIP CEBPD
6 autism 31.1 MECP2 MAPT FOXP2 DNAAF4 CNTNAP2 CELF4
7 aphasia 31.0 TARDBP MAPT GRN FUS FOXP2 CHMP2B
8 autism spectrum disorder 31.0 MECP2 FOXP2 DNAAF4 CNTNAP2 CMIP
9 dysgraphia 30.8 TARDBP MAPT GRN DNAAF4 CHMP2B CBSL
10 agraphia 30.8 TARDBP MAPT IQCB1 GRN CBSL C9orf72
11 echolalia 30.8 MECP2 MAPT GRN FOXP2 CNTNAP2 CEBPD
12 attention deficit-hyperactivity disorder 30.6 MECP2 KIAA0319 FOXP2 CNTNAP2 ADAMTS2
13 lateral sclerosis 30.6 TARDBP FUS CHMP2B C9orf72
14 frontotemporal dementia 30.6 TARDBP MAPT GRN FUS CHMP2B C9orf72
15 learning disability 30.6 MECP2 MAPT KIAA0319 IQCB1 FOXP2 DNAAF4
16 progressive non-fluent aphasia 30.5 MAPT GRN CHMP2B C9orf72
17 progressive muscular atrophy 30.5 TARDBP FUS CHMP2B C9orf72
18 amyotrophic lateral sclerosis 1 30.5 TARDBP MAPT GRN FUS CHMP2B C9orf72
19 associative agnosia 30.5 TARDBP MAPT GRN CHMP2B C9orf72
20 prion disease 30.5 TARDBP MAPT APOE
21 dyscalculia 30.5 TARDBP KIAA0319 IQCB1 GRN DNAAF4 CHMP2B
22 dementia 30.5 TARDBP MAPT GRN FUS CHMP2B C9orf72
23 akinetic mutism 30.5 TARDBP MAPT
24 semantic dementia 30.5 TARDBP MAPT GRN CHMP2B C9orf72 APOE
25 movement disease 30.5 TARDBP MAPT FUS CBSL C9orf72
26 prosopagnosia 30.4 TARDBP MAPT GRN CHMP2B C9orf72 ASPRV1
27 specific language impairment 30.4 KIAA0319 IQCB1 FOXP2 DNAAF4 CNTNAP2 CMIP
28 pervasive developmental disorder 30.4 MECP2 IQCB1 FOXP2 CNTNAP2 CELF4 CEBPD
29 frontotemporal lobar degeneration with tdp43 inclusions, grn-related 30.3 MAPT GRN
30 articulation disorder 30.3 FOXP2 CNTNAP2 CEBPD ASPRV1
31 disease of mental health 30.3 TARDBP MECP2 MAPT GRN C9orf72 ASPRV1
32 supranuclear palsy, progressive, 1 30.2 TARDBP MAPT GRN FUS CHMP2B CBSL
33 apraxia 30.2 MAPT GRN FOXP2 CNTNAP2 C9orf72 APOE
34 pick disease of brain 30.2 TARDBP MAPT GRN FUS CHMP2B CBSL
35 corticobasal degeneration 30.2 TARDBP MAPT
36 mutism 30.2 TARDBP MAPT GRN CNTNAP2 CHMP2B C9orf72
37 reading disorder 30.2 KIAA0319 IQCB1 FOXP2 DNAAF4 CNTNAP2 CMIP
38 motor neuron disease 30.1 TARDBP MAPT GRN FUS C9orf72 APOE
39 nominal aphasia 30.0 TARDBP MAPT GRN FUS CHMP2B CBSL
40 foxp2-related speech and language disorders 12.6
41 childhood apraxia of speech 11.7
42 epilepsy-aphasia spectrum 11.5
43 cerebral atrophy 11.2
44 swallowing disorders 11.2
45 cluttering 11.1
46 mixed receptive-expressive language disorder 11.0
47 meniere disease 10.9
48 usher syndrome 10.9
49 acoustic neuroma 10.9
50 agnosia 10.9

Graphical network of the top 20 diseases related to Speech and Communication Disorders:



Diseases related to Speech and Communication Disorders

Symptoms & Phenotypes for Speech and Communication Disorders

UMLS symptoms related to Speech and Communication Disorders:


lethargy, other symbolic dysfunction, aprosodia, neurobehavioral manifestations

MGI Mouse Phenotypes related to Speech and Communication Disorders:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.27 APOE C9orf72 CBSL CEBPD CELF4 CNTNAP2
2 growth/size/body region MP:0005378 10.22 ADAMTS2 APOE C9orf72 CBSL CELF4 CNTNAP2
3 cellular MP:0005384 10.21 APOE C9orf72 CBSL CEBPD CNTNAP2 DNAAF4
4 immune system MP:0005387 10.15 APOE C9orf72 CBSL CEBPD CELF4 CMIP
5 integument MP:0010771 10.06 ADAMTS2 APOE ASPRV1 C9orf72 CBSL CEBPD
6 mortality/aging MP:0010768 10 APOE C9orf72 CBSL CEBPD CELF4 CHMP2B
7 liver/biliary system MP:0005370 9.86 APOE C9orf72 CBSL CELF4 CMIP GATM
8 nervous system MP:0003631 9.8 APOE C9orf72 CBSL CELF4 CHMP2B CMIP
9 respiratory system MP:0005388 9.17 ADAMTS2 APOE C9orf72 CBSL CEBPD DNAAF4

Drugs & Therapeutics for Speech and Communication Disorders

Drugs for Speech and Communication Disorders (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 109)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Oxcarbazepine Approved Phase 4 28721-07-5 34312
2
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
3
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
4
Diazepam Approved, Illicit, Investigational, Vet_approved Phase 4 439-14-5 3016
5
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
6 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
7
Levetiracetam Approved Phase 4 102767-28-2 441341
8
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554
9
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
10
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
11
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
12 Omega 3 Fatty Acid Phase 4
13 Tranquilizing Agents Phase 4
14 Neurotransmitter Agents Phase 4
15 Psychotropic Drugs Phase 4
16 Central Nervous System Depressants Phase 4
17 Anesthetics Phase 4
18 Anesthetics, General Phase 4
19 Adjuvants, Anesthesia Phase 4
20 Anesthetics, Intravenous Phase 4
21 Autonomic Agents Phase 4
22 Anti-Anxiety Agents Phase 4
23 Antiemetics Phase 4
24 Gastrointestinal Agents Phase 4
25 Methylprednisolone Acetate Phase 4
26 GABA Agents Phase 4
27 Anticonvulsants Phase 4
28 Hypnotics and Sedatives Phase 4
29 GABA Modulators Phase 4
30 Neuromuscular Agents Phase 4
31
Cycloserine Approved Phase 3 68-41-7 401 6234
32
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
33
Memantine Approved, Investigational Phase 3 19982-08-2 4054
34 Ecopipam Investigational Phase 2, Phase 3 112108-01-7
35 Antipsychotic Agents Phase 2, Phase 3
36 Dopamine Antagonists Phase 2, Phase 3
37 Anti-Infective Agents Phase 3
38 Renal Agents Phase 3
39 Antitubercular Agents Phase 3
40 Antibiotics, Antitubercular Phase 3
41 Anti-Bacterial Agents Phase 3
42 Anti-Infective Agents, Urinary Phase 3
43 Antimetabolites Phase 3
44 Dopamine Agents Phase 3
45 Antiparkinson Agents Phase 3
46 Excitatory Amino Acid Antagonists Phase 3
47 Excitatory Amino Acids Phase 3
48 Hormones Phase 3
49 Estrogens Phase 3
50 Hormone Antagonists Phase 3

Interventional clinical trials:

(show top 50) (show all 149)
# Name Status NCT ID Phase Drugs
1 Omega 3/6 Fatty Acids for Reading in Children: A Randomised, Double-blind, Placebo-controlled Trial in 9-year-old Mainstream Schoolchildren in Sweden Completed NCT02557477 Phase 4
2 Longitudinal Multi-Modality Imaging in Progressive Apraxia of Speech Recruiting NCT01818661 Phase 4 AV-1451
3 Electroclinical Effect of Diazepam and Steroid in Patients With Benign Childhood Epilepsy With Centrotemporal Spikes Not yet recruiting NCT03490487 Phase 4 conventional antiepileptic drugs;oral steroid;Diazepam
4 An Open-label Study to Evaluate the Efficacy and Tolerability of Ecopipam in Adults With Childhood Onset Fluency Disorder (Stuttering). Unknown status NCT02909088 Phase 2, Phase 3 Ecopipam 50mg;Ecopipam 100mg
5 Effectiveness of a Parent-Based Language Intervention Group Program for Two-Year-Old Children With Language Delay Unknown status NCT00625261 Phase 3
6 A Comparison of Language Intervention Programs Completed NCT00033150 Phase 3
7 A Randomized Controlled Trial of D-Cycloserine in Autism Completed NCT00198120 Phase 3 D-cycloserine;Placebo
8 Use of Acupuncture In Autistic Spectrum Disorder Completed NCT00346736 Phase 3
9 Tinnitus Retraining Therapy Trial Completed NCT01177137 Phase 3
10 Memantine for the Treatment of Social Deficits in Youth With Disorders of Impaired Social Interactions: A Randomized-controlled Trial Recruiting NCT03553875 Phase 3 Memantine Hydrochloride;Placebo
11 Raloxifene Augmentation in Patients With a Schizophrenia Spectrum Disorder to Reduce Symptoms and Improve Cognition Recruiting NCT03043820 Phase 3 Raloxifene;Placebo
12 Effects of Frequency Modulation (FM) Assistive Listening Device Systems on Listening and Related Skills in Children With Auditory Processing Disorders (APD) Unknown status NCT02353091 Phase 2
13 AMALS: Addressing Multiple Aspects of Language Simultaneously: A Randomized Clinical Trial Completed NCT00840060 Phase 2
14 Effects of Intensity of Early Communication Intervention Completed NCT00723151 Phase 2
15 Transcranial Direct Current Stimulation and Aphasia Treatment Outcomes Completed NCT01686373 Phase 2
16 Treating Intention In Aphasia: Neuroplastic Substrates Completed NCT00567242 Phase 1, Phase 2
17 A Phase II, Randomized, Double-blind, Placebo-controlled Study of Myrosinase-enriched Glucoraphanin, a Sulforaphane Precursor System, in Autism Spectrum Disorder Completed NCT02909959 Phase 2 Sulforaphane;Placebo
18 Effect Of Verb Network Strengthening Treatment on Lexical Retrieval in Aphasia Completed NCT01300624 Phase 2
19 Characterization and Sequential Pharmacotherapy of Severe Mood Dysregulation Completed NCT01714310 Phase 2 lisdexamfetamine;Placebo;fluoxetine
20 Maximizing Outcomes for Preschoolers With Developmental Language Disorder: Testing the Effects of a Sequentially Targeted Naturalistic Intervention. Recruiting NCT03782493 Phase 2
21 Word by Word: Building Sentences With Preschoolers Who Use AAC Recruiting NCT03538925 Phase 2
22 Correcting Residual Errors With Spectral, Ultrasound, and Traditional Speech Therapy: A Randomized Controlled Trial Recruiting NCT03737318 Phase 2
23 Sulforaphane Treatment of Children With Autism Spectrum Disorder (ASD) Active, not recruiting NCT02561481 Phase 1, Phase 2 Sulforaphane;Placebo
24 Treatment of Social and Language Deficits With Leucovorin for Young Children With Autism Not yet recruiting NCT04060030 Phase 2 Levoleucovorin Calcium
25 Early Treatment of Language Impairment in Young Children With Autism Spectrum Disorder With Leucovorin Calcium Not yet recruiting NCT04060017 Phase 2 Levoleucovorin Calcium
26 Leucovorin for the Treatment of Language Impairment in Children With Autism Spectrum Disorder Not yet recruiting NCT02839915 Phase 2 Folinic Acid
27 Head-Mounted Vibrotactile Prosthesis for Patients With Chronic Postural Instability Completed NCT00889824 Phase 1
28 The Effect of Inhaled Corticosteroids on Vocal Fold Nodules in Children: A Pilot Study Recruiting NCT03040596 Phase 1 Fluticasone propionate
29 To Investigate the Event Related Potentials (ERPs) of Patients With Brain Lesions Unknown status NCT01254500
30 Concordance of Pain Detection in Patients by Doloplus® and Algoplus® Behavioural Scales. Unknown status NCT02174744
31 Language and Motricity in Preterm School Age Children Unknown status NCT02811029
32 Oral Language in Children With Down Syndrome: Lexical, Syntactic and Semantic Aspects Unknown status NCT00952354
33 INTERNATIONAL VALIDATION STUDY OF THE ALGOPLUS SCALE IN FIVE LANGUAGES Unknown status NCT02018614
34 Effectiveness of Delivering Vocal Training Via Telepractice for Elderly Using Integrated Communication Technology Unknown status NCT02922309
35 Study of the Interest of Proprioceptive Therapy as a Complement to Speech Therapy in Children With Reading Difficulties Unknown status NCT02861599
36 Interest of Combining Speech Therapy With a Non-invasive Brain Stimulation (tDCS) for the Aphasic Patient Unknown status NCT02612753
37 Clinical and Genetic Study of Autism Spectrum Disorder Unknown status NCT00494754
38 Structural and Functional Connectivity in Autism Spectrum Disorders by Using Diffusion Spectrum Imaging and Functional Magnetic Resonance Imaging Studies Unknown status NCT00755430
39 MP-LoGa: Bi-hemispheral Transcranial Direct Current Stimulation to Improve the Severe Aphasia in Subacute Stroke Patients: a Randomized, Placebo-controlled, Double Blinded Multi-center Trial Unknown status NCT02395874
40 Impact of the Use of the Scale ALGOPLUS® on the Prescriptions of Analgesics in Emergency Department on Patients of 75 Years Old or More Unknown status NCT02258503
41 Linguistic, Anatomic/Metabolic and Biologic Characterisation of the Three Main Variants of Primary Progressive Aphasia : Towards the Rationale for Drug Trials and Specific Language Rehabilitations Unknown status NCT02297035
42 Phonological Treatment Paired With Intensive Speech Therapy Promotes Reading Recovery in Chronic Aphasia Unknown status NCT02799017
43 Transcranial Direct Current Stimulation (tDCS) an Adjuvant to Intensive Speech Therapy in Chronic Post Stroke Aphasia Unknown status NCT02801864
44 Evaluation of Mental Flexibility Through Language Tests in Adolescents With Frontal Brain Damage and in Healthy Children in Ages 8-17 Completed NCT01696292
45 Pivotal Response Treatment for Individuals With Intellectual Disabilities Completed NCT01988623
46 Language Stimuli Screening in Children Completed NCT00016796
47 An Efficacy Trial of Milieu Teaching Language Intervention in Children With Language Disorders Completed NCT01975922
48 Assessing the Effectiveness of Communication Therapy in the North West (The ACT NoW Pilot Study) Completed NCT00158106
49 Developmental Language Difficulties: Behavioural and Electrophysiological Studies of the Connections Between Spoken and Written Language and Specificity of These Disorders Completed NCT02872870
50 Experimental Word Learning in Children With Normal Development and Children With Language Impairment Completed NCT00607334

Search NIH Clinical Center for Speech and Communication Disorders

Cochrane evidence based reviews: communication disorders

Genetic Tests for Speech and Communication Disorders

Anatomical Context for Speech and Communication Disorders

MalaCards organs/tissues related to Speech and Communication Disorders:

40
Brain, Testes, Tongue, Cortex, Thalamus, Temporal Lobe, Eye

Publications for Speech and Communication Disorders

Articles related to Speech and Communication Disorders:

(show top 50) (show all 1655)
# Title Authors PMID Year
1
Intensive group behavioral treatment (IGBT) for children with selective mutism: A preliminary randomized clinical trial. 42
31294589 2019
2
Clinical Trial for Stuttering Treatment: pilot study about dog participation in the therapy session. 42
31721913 2019
3
Causality and Speech, Language and Hearing Sciences: epidemiological approach. 42
31664371 2019
4
Recent advances in the genetics of language impairment. 54 61
20193051 2010
5
Assessing the impact of FOXP1 mutations on developmental verbal dyspraxia. 54 61
19352412 2009
6
FOXP genes, neural development, speech and language disorders. 54 61
20429420 2009
7
Identification of the transcriptional targets of FOXP2, a gene linked to speech and language, in developing human brain. 54 61
17999357 2007
8
High-throughput analysis of promoter occupancy reveals direct neural targets of FOXP2, a gene mutated in speech and language disorders. 54 61
17999362 2007
9
Mutation screening of FOXP2 in individuals diagnosed with autistic disorder. 54 61
12655497 2003
10
Cortical stimulation in aphasia following ischemic stroke: toward model-guided electrical neuromodulation. 61
32020368 2020
11
How language and inhibition influence analogical reasoning in children with or without developmental language disorder? 61
31599197 2020
12
Patient-Reported Outcomes and Evidence-Based Practice in Speech-Language Pathology. 61
32011905 2020
13
Speech and Language Disorders in Friedreich Ataxia: Highlights on Phenomenology, Assessment, and Therapy. 61
31701351 2020
14
Speech profiles of Spanish-Catalan children with developmental language disorder. 61
31112662 2020
15
Altered efficiency of white matter connections for language function in children with language disorder. 61
32004807 2020
16
The effects of gender and academic achievement on reading fluency among Year 2 Malaysian school children. 61
32018165 2020
17
Treating Deficits in Auditory Processing Abilities. 61
32004103 2020
18
Language ability and adult homelessness. 61
31925870 2020
19
Telerehabilitation services for stroke. 61
32002991 2020
20
Phonogram and word decoding patterns in children with developmental language disorders: Evidence for protracted periods of graphophonemic decoding. 61
32028205 2020
21
An interprofessional early childhood training program: speech-language pathology and music therapy student outcomes and reflections. 61
31838928 2019
22
The impact of expressive language development and the left inferior longitudinal fasciculus on listening and reading comprehension. 61
31838999 2019
23
Communicative and swallowing disorders in anoxic patients: A retrospective study on clinical outcomes and performance measures. 61
31868687 2019
24
Degenerative and Vascular Fluent Aphasia: Looking for Differences. 61
31800483 2019
25
Play Sports for a Quieter Brain: Evidence From Division I Collegiate Athletes. 61
31813316 2019
26
Auditory frequency discrimination in developmental dyslexia: A meta-analysis. 61
31877576 2019
27
Middle longitudinal fascicle is associated with semantic processing deficits in primary progressive aphasia. 61
31865024 2019
28
The mini-mental state examination (MMSE) from a language perspective: an analysis of test interaction. 61
31739693 2019
29
Cortical Foxp2 Supports Behavioral Flexibility and Developmental Dopamine D1 Receptor Expression. 61
31711176 2019
30
Establishing consensus among community clinicians on how to categorize and define preschoolers' speech and language impairments at assessment. 61
31434024 2019
31
Acoustic Analysis of Crying Signal in Infants with Disabling Hearing Impairment. 61
30055981 2019
32
A novel mutation in a common pathogenic gene (SETD5) associated with intellectual disability: A case report. 61
31656537 2019
33
Incidence of frontotemporal disorders in Olmsted County: A population-based study. 61
31784373 2019
34
Heterogeneous neurodevelopmental disorders in children with Kawasaki disease: what is new today? 61
31684911 2019
35
Autism, Gastrointestinal Symptoms and Modulation of Gut Microbiota by Nutritional Interventions. 61
31752095 2019
36
Speech-language development as proceduralization and skill learning: Implications for assessment and intervention. 61
31302384 2019
37
Late-Emerging Developmental Language Disorders in English-Speaking Monolinguals and English-Language Learners: A Longitudinal Perspective. 61
31387462 2019
38
'It depends': Characterizing speech and language therapy for preschool children with developmental speech and language disorders. 61
31531914 2019
39
Working with the parents and families of children with developmental language disorders: An international perspective. 61
31425855 2019
40
Language and language disorders: neuroscience to clinical practice. 61
31350297 2019
41
Assessment of implicit language and theory of mind in multiple sclerosis. 61
31586684 2019
42
Western Aphasia Battery-Revised Profiles in Primary Progressive Aphasia and Primary Progressive Apraxia of Speech. 61
31639312 2019
43
Mice carrying a humanized Foxp2 knock-in allele show region-specific shifts of striatal Foxp2 expression levels. 61
30808549 2019
44
The Relationship Among Screen Use, Sleep, and Emotional/Behavioral Difficulties in Preschool Children with Neurodevelopmental Disorders. 61
31107771 2019
45
Sex Differences in Functional Brain Networks for Language. 61
31512720 2019
46
Identifying Children With Clinical Language Disorder: An Application of Machine-Learning Classification. 61
31064260 2019
47
Autism spectrum disorder and neurodevelopmental delays in children with giant omphalocele. 61
31196668 2019
48
Considering proceduralization through the lens of adolescents with developmental language disorders: Commentary on Kamhi (2019). 61
31558287 2019
49
Preoperative augmentative and alternative communication enhancement in pediatric tracheostomy. 61
31487042 2019
50
Modifying a language screening tool for three-year-old children identified severe language disorders six months earlier. 61
30896050 2019

Variations for Speech and Communication Disorders

Expression for Speech and Communication Disorders

Search GEO for disease gene expression data for Speech and Communication Disorders.

Pathways for Speech and Communication Disorders

Pathways related to Speech and Communication Disorders according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.56 TARDBP MECP2 MAPT CNTNAP2 APOE

GO Terms for Speech and Communication Disorders

Cellular components related to Speech and Communication Disorders according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 dendrite GO:0030425 9.35 MAPT FUS CNTNAP2 C9orf72 APOE
2 axolemma GO:0030673 9.16 MAPT CNTNAP2
3 main axon GO:0044304 8.62 MAPT C9orf72

Biological processes related to Speech and Communication Disorders according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of gene expression GO:0010629 9.56 TARDBP MECP2 MAPT APOE
2 regulation of proteasomal protein catabolic process GO:0061136 9.4 DNAAF4 APOE
3 stress granule assembly GO:0034063 9.37 MAPT C9orf72
4 gene expression GO:0010467 9.32 TARDBP FUS
5 multicellular organismal response to stress GO:0033555 9.16 MECP2 KIAA0319
6 vocal learning GO:0042297 8.96 FOXP2 CNTNAP2
7 neuron projection development GO:0031175 8.92 MECP2 MAPT CNTNAP2 APOE

Molecular functions related to Speech and Communication Disorders according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 lipoprotein particle binding GO:0071813 8.62 MAPT APOE

Sources for Speech and Communication Disorders

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....